In this Review, the authors highlight the potential for efficacy genetics to drive drug development and guide treatment options. They argue for the integration of routine pharmacogenetic screening into clinical development and propose strategies for identifying efficacy loci for marketed drugs.
- Matthew R. Nelson
- Toby Johnson
- Dawn M. Waterworth